Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.
Loss of huntingtin-mediated BDNF gene transcription has been shown to occur in HD and thus contribute to the degeneration of the striatum. Several studies have indicated that an increase in BDNF levels is associated with neuroprotection and amelioration of neurological signs in animal models of HD....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3659095?pdf=render |
| _version_ | 1819010076881453056 |
|---|---|
| author | Carmela Giampà Elena Montagna Clemente Dato Mariarosa A B Melone Giorgio Bernardi Francesca Romana Fusco |
| author_facet | Carmela Giampà Elena Montagna Clemente Dato Mariarosa A B Melone Giorgio Bernardi Francesca Romana Fusco |
| author_sort | Carmela Giampà |
| collection | DOAJ |
| description | Loss of huntingtin-mediated BDNF gene transcription has been shown to occur in HD and thus contribute to the degeneration of the striatum. Several studies have indicated that an increase in BDNF levels is associated with neuroprotection and amelioration of neurological signs in animal models of HD. In a recent study, an increase in BDNF mRNA and protein levels was recorded in mice administered recombinant BDNF peripherally. Chronic, indwelling osmotic mini-pumps containing either recombinant BDNF or saline were surgically placed in R6/2 or wild-type mice from 4 weeks of age until euthanasia. Neurological evaluation (paw clasping, rotarod performance, locomotor activity in an open field) was performed. After transcardial perfusion, histological and immunohistochemical studies were performed. We found that BDNF- treated R6/2 mice survived longer and displayed less severe signs of neurological dysfunction than the vehicle treated ones. Primary outcome measures such as brain volume, striatal atrophy, size and morphology of striatal neurons, neuronal intranuclear inclusions and microglial reaction confirmed a neuroprotective effect of the compound. BDNF was effective in increasing significantly the levels of activated CREB and of BDNF the striatal spiny neurons. Moreover, systemically administered BDNF increased the synthesis of BDNF as demonstrated by RT-PCR, and this might account for the beneficial effects observed in this model. |
| first_indexed | 2024-12-21T01:06:31Z |
| format | Article |
| id | doaj.art-4249ed8fe94c4bc5aced6e9c7c0ae9f8 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T01:06:31Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-4249ed8fe94c4bc5aced6e9c7c0ae9f82022-12-21T19:21:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0185e6403710.1371/journal.pone.0064037Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.Carmela GiampàElena MontagnaClemente DatoMariarosa A B MeloneGiorgio BernardiFrancesca Romana FuscoLoss of huntingtin-mediated BDNF gene transcription has been shown to occur in HD and thus contribute to the degeneration of the striatum. Several studies have indicated that an increase in BDNF levels is associated with neuroprotection and amelioration of neurological signs in animal models of HD. In a recent study, an increase in BDNF mRNA and protein levels was recorded in mice administered recombinant BDNF peripherally. Chronic, indwelling osmotic mini-pumps containing either recombinant BDNF or saline were surgically placed in R6/2 or wild-type mice from 4 weeks of age until euthanasia. Neurological evaluation (paw clasping, rotarod performance, locomotor activity in an open field) was performed. After transcardial perfusion, histological and immunohistochemical studies were performed. We found that BDNF- treated R6/2 mice survived longer and displayed less severe signs of neurological dysfunction than the vehicle treated ones. Primary outcome measures such as brain volume, striatal atrophy, size and morphology of striatal neurons, neuronal intranuclear inclusions and microglial reaction confirmed a neuroprotective effect of the compound. BDNF was effective in increasing significantly the levels of activated CREB and of BDNF the striatal spiny neurons. Moreover, systemically administered BDNF increased the synthesis of BDNF as demonstrated by RT-PCR, and this might account for the beneficial effects observed in this model.http://europepmc.org/articles/PMC3659095?pdf=render |
| spellingShingle | Carmela Giampà Elena Montagna Clemente Dato Mariarosa A B Melone Giorgio Bernardi Francesca Romana Fusco Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. PLoS ONE |
| title | Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. |
| title_full | Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. |
| title_fullStr | Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. |
| title_full_unstemmed | Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. |
| title_short | Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. |
| title_sort | systemic delivery of recombinant brain derived neurotrophic factor bdnf in the r6 2 mouse model of huntington s disease |
| url | http://europepmc.org/articles/PMC3659095?pdf=render |
| work_keys_str_mv | AT carmelagiampa systemicdeliveryofrecombinantbrainderivedneurotrophicfactorbdnfinther62mousemodelofhuntingtonsdisease AT elenamontagna systemicdeliveryofrecombinantbrainderivedneurotrophicfactorbdnfinther62mousemodelofhuntingtonsdisease AT clementedato systemicdeliveryofrecombinantbrainderivedneurotrophicfactorbdnfinther62mousemodelofhuntingtonsdisease AT mariarosaabmelone systemicdeliveryofrecombinantbrainderivedneurotrophicfactorbdnfinther62mousemodelofhuntingtonsdisease AT giorgiobernardi systemicdeliveryofrecombinantbrainderivedneurotrophicfactorbdnfinther62mousemodelofhuntingtonsdisease AT francescaromanafusco systemicdeliveryofrecombinantbrainderivedneurotrophicfactorbdnfinther62mousemodelofhuntingtonsdisease |